Oncology Peer Review On-The-Go: Barriers to Pancreatic Cancer Clinical Trial Enrollment

November 11, 2020
Matthew Fowler
Matthew Fowler

The latest installment of “Oncology Peer Review On-The-Go” dissects original research published in the journal ONCOLOGY regarding potential barriers to clinical trial enrollment for patients with pancreatic cancer.

This episode of "Oncology Peer Review On-The-Go" examines an article published in the October issue of the journal ONCOLOGY, titled “Barriers to Clinical Trial Enrollment in Patients With Pancreatic Adenocarcinoma Who Are Eligible for Early-Phase Clinical Trials.”

The piece was written by Rachael Galvin, DO, MPH, Christine Chung, DO, Ella Achenbach, Oliwier Dziadkowiec, PhD, and Shiraj Sen, MD, PhD, and focuses on what keeps patients with this aggressive form of pancreatic cancer from pursuing enrollment in clinical trials. For a summary of the article, CancerNetwork spoke with Galvin, lead author of the study who is from the Swedish Medical Center in Englewood, Colorado.

For the article’s response perspective, CancerNetwork spoke with Michael Lee, MD, from The University of Texas MD Anderson Cancer Center in Houston. Lee discussed his perspective piece published on CancerNetwork titled “Barriers to Pancreatic Cancer Clinical Trials Enrollment.” The piece examines Galvin’s work and clinical trial enrollment for the disease as a whole.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.